The regimen of bexmarilimab and azacitidine (Vidaza) demonstrated a highly promising efficacy profile with a manageable ...

In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma Congress on the evolving treatment landscape for relapsed or refractory diffuse large B-cell ...

The 5-year lung cancer survival rate has increased more than 25% over the past decade, highlighting the impact of increased ...

Nurix Therapeutics recently announced the initiation of the pivotal Phase 2 DAYBreak trial of its BTK degrader candidate NX-5948 in relapsed or refractory chronic lymphocytic leukemia, alongside plans ...

A cross-continental study suggests that in the treatment of acute myeloid leukemia, age affects survival, independent of ...

MemorialCare Medical Group has appointed four accomplished physicians as Medical Directors: Rachael Lopez, M.D., Medical Director of Obstetrics and Gynecology; Irina Sachelarie, M.D., Medical Director ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

CURE had the privilege of attending the Hairy Cell Leukemia Foundation 2025 Conference in Bologna, Italy, where medical experts gathered to discuss advances in research, treatment ...

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host ...

Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease - ...

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim ...

A Ghanaian researcher, Nana Kwame Kwabi Boateng, is part of a team of scientists that has made a groundbreaking discovery, ...